Alimera reports 36-month outcomes from ILUVIEN Phase 3 FAME study for DME 28.

Peter Campochiaro, M.D., will show results at Angiogenesis, Exudation and Degeneration 2011, 12 February, in Miami, Fla. Alimera Sciences, Inc. Sufferers in the trials were randomized to receive either high dose ILUVIEN, low dose ILUVIEN or control treatment. Alimera previously shown data for both the low and high dosage patient outcomes at month 24. Based on these data, Alimera submitted a fresh Drug Program on June 29, 2010 for authorization of only the low dose.There was no factor between treatment organizations in follow-up prices or known reasons for missed tests. Neuropsychological data for the 1156 patients with full and matched test measures at baseline and at 1 year of follow-up were analyzed . This number of records represents a sample size which allows detection of a notable difference no more than 0.20 SD, with a charged power of 80 and a P value of 0.01 indicating statistical significance, which was equivalent to a difference of 0. As compared with patients with nonmatched baseline and 1-year records, the 1156 sufferers were young , were more likely to be white , and had a lesser estimated threat of 30-day time operative death . There have been no significant variations between your treatment groups in age group, education, medical features, or the Beck Despair Inventory score; there were significant but not relevant differences in three baseline cognitive scores clinically.